ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.83 -0.60%

-$0.13 today

Market cap
$3.08B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.89M

Average 1.66M

ACAD Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 175.47M shares rose 2.8% year over year, in line with the +2.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.8% toward the trailing-twelve-month pace of +2.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
175.47M+1.5% QoQ
Last fiscal yearDec 2025
171.36M+3.0% YoY
LTMSep 2026
173.1M+2.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.8%——
1 year+3.0%——
3-year CAGR+2.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
171.36M USD
Year-over-year change
+3.0%
4-year CAGR
+1.7%

Weighted Avg Shares (Diluted) vs competitors

How ACAD compares with its peers on the latest reported figures

  • ACAD's LTM Sep 2026 weighted avg shares (diluted) of 173.1M shares is the highest of the 11 companies compared; the peer median is 42.47M shares.
  • Its year-over-year change of +2.8% is the 9th highest of 10, against a peer median of +4.3%.
  • Over three fiscal years its annual growth of +2.0% compares with a peer median of +3.8%.
ACAD Competitors Peer median
Weighted Avg Shares (Diluted) for ACAD and competitors
Company Period LTM YoY 3-year CAGR
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026173.1M +2.8%+2.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
AVXLAnavex Life Sciences Corp.LTM Dec 202586.34M +2.9%+3.5%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.1%
AXSMAxsome Therapeutics, Inc.LTM Jun 202650.84M +4.3%+7.0%
MPLTMapLight Therapeutics, Inc.LTM Mar 202643.04M +3.9%+2.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
PRAXPraxis Precision Medicines, Inc.LTM Sep 202627.42M +29.8%+94.2%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
Peer median (excluding ACAD) 42.47M+4.3%+3.8%

Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.15M517.24M726.44M957.8M1.07B
Cost of Revenue19.14M10.17M45.73M81.84M89M
Gross Profit465M507.07M680.71M875.96M982.51M
Gross Margin96.0%98.0%93.7%91.5%91.7%
Research & Development239.42M361.58M351.62M303.25M328.8M
Selling, General & Admin396.03M369.09M402.47M488.43M548.89M
Operating Expenses635.44M730.67M754.09M645.16M877.7M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
EBITDA(164.18M)(211.42M)(45.48M)100.16M150.66M
EBITDA Margin-33.9%-40.9%-6.3%10.5%14.1%
Operating Income(170.44M)(223.6M)(73.38M)230.79M104.81M
Operating Margin-35.2%-43.2%-10.1%24.1%9.8%
Interest Income591K6.61M17.23M25.46M31.72M
Interest Expense00000
Other Income / Expenses2.92M10.15M22.34M27.28M34.09M
Income Before Tax(167.52M)(213.44M)(51.04M)258.08M138.9M
Pre-Tax Margin-34.6%-41.3%-7.0%26.9%13.0%
Income Tax Expense351K2.53M10.25M31.62M(252.1M)
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Net Margin-34.7%-41.8%-8.4%23.6%36.5%
EPS (Basic)(1.05)(1.34)(0.37)1.372.32
EPS (Diluted)(1.05)(1.34)(0.37)1.362.29
Weighted Avg Shares160.49M161.68M163.82M165.72M169.34M
Weighted Avg Shares (Diluted)160.49M161.68M163.82M166.36M171.36M

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.